SpectraCure ABOSTO:SPEC -4.65% PB Ratio is 0.24 as of Jun. 26, 2026, which is 99% below its 10-year median of 21.65. The stock has 1 warning sign investors should review. Among 788 Medical Devices & Instruments companies, SpectraCure AB ranks better than 98.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), SpectraCure AB's share price is kr0.0431. SpectraCure AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr0.18. Hence, SpectraCure AB's PB Ratio of today is 0.24.
Good Sign:
SpectraCure AB stock PB Ratio (=0.26) is close to 10-year low of 0.26.
The historical rank and industry rank for SpectraCure AB's PB Ratio or its related term are showing as below:
OSTO:SPEC'
s PB Ratio Range Over the Past 10 Years
Min: 0.26 Med: 21.65 Max: 144.16
Current: 0.26
During the past 12 years, SpectraCure AB's highest PB Ratio was 144.16. The lowest was 0.26. And the median was 21.65.
OSTO:SPEC's PB Ratio is ranked better than 98.35% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs OSTO:SPEC: 0.26
During the past 12 months, SpectraCure AB's average Book Value Per Share Growth Rate was -60.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.30% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of SpectraCure AB was 105.20% per year. The lowest was -29.80% per year. And the median was 13.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SpectraCure AB PB Ratio Related Terms
SpectraCure AB PB Ratio Historical Data
* Premium members only.
The historical data trend for SpectraCure AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SpectraCure AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpectraCure AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SpectraCure AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where SpectraCure AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
SpectraCure AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SpectraCure AB (OSTO:SPEC) has a PB Ratio of 0.24 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SpectraCure AB and its competitors. This is 99% below median its historical median of 21.65. Over the past decade, SpectraCure AB's PB Ratio has ranged from 0.26 to 144.16. According to the industry distribution chart, SpectraCure AB ranks #13 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 1.6%.
Is SpectraCure AB's PB Ratio too high?
SpectraCure AB's current PB Ratio of 0.24 is 99% below median its 10-year median of 21.65. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 144.16. The Medical Devices & Instruments industry median PB Ratio is 2.02. SpectraCure AB's value of 0.24 is 88.1% below this industry median. Based on the distribution chart, SpectraCure AB ranks #13 out of 788 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does SpectraCure AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SpectraCure AB ranks #13 out of 788 companies for PB Ratio. This places SpectraCure AB in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.02. SpectraCure AB's value of 0.24 is 88.1% below this benchmark. Historically, SpectraCure AB's own PB Ratio has ranged from 0.26 to 144.16 over the past decade. While the company's 10-year median is 21.65 vs. the industry median of 2.02, SpectraCure AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpectraCure AB's current PB Ratio of 0.24 is 88.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SpectraCure AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpectraCure AB's current PB Ratio is 0.24, which is 99% below median its own 10-year median of 21.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpectraCure AB stock overvalued right now?
SpectraCure AB (OSTO:SPEC) has a current PB Ratio of 0.24. The current PB Ratio is 0.24, which is 99% below median its 10-year median of 21.65 and 88.1% below the Medical Devices & Instruments industry median of 2.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SpectraCure AB (OSTO:SPEC), the current PB Ratio is 0.24 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPEC has been successfully added to your 